NCT02171988View on ClinicalTrials.gov

Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS)

PHASE4CompletedINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 31, 2014

Primary Completion Date

February 29, 2016

Study Completion Date

December 31, 2016

Conditions
Postural Orthostatic Tachycardia Syndrome
Interventions
DRUG

Propranolol

Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable

DRUG

Bisoprolol

Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable

DRUG

Propranolol+pyridostigmine

Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.

DRUG

Bisoprolol+pyridostgmine

Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable

Trial Locations (1)

Unknown

Seoul National University Hospital, Seoul

All Listed Sponsors
lead

Seoul National University Hospital

OTHER

NCT02171988 - Effect of Medical Treatment and Prognosis of Postural Orthostatic Tachycardia Syndrome (POTS) | Biotech Hunter | Biotech Hunter